Mechanism of Action in Migraine Therapeutics: Does It Matter to Clinicians and Patients?

Industry-Sponsored Event

Sponsored by Lilly

Not Eligible for CME Credits Jessica Ailani, MD, FAHS MedStar Georgetown University Hospital Peter J. Goadsby, MD, PhD, FAHS University of California, Los Angeles Paul G. Mathew, MD, DNBPAS, FAHS Harvard Medical School

This symposium will explore why mechanism of action (MOA) should be a consideration in clinical decision-making around acute and preventive treatments for migraine. The discussion will focus on increasing your confidence to include MOA considerations when making treatment decisions and encouraging conversations with your patients around how MOA could impact their treatment.